These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33276405)

  • 21. Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience.
    Özütemiz C; Karachunski P; Nascene DR
    Diagn Interv Radiol; 2020 Nov; 26(6):596-602. PubMed ID: 32436843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of three-dimensional printing of a lumbar skeletal model for intrathecal administration of nusinersen: a brief technical report.
    Abe H; Inoue R; Tsuchida R; Azuma K; Ino K; Konishi M; Hozumi J; Sumitani M
    Reg Anesth Pain Med; 2020 Oct; 45(10):757-760. PubMed ID: 32817238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
    Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
    Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.
    Weaver JJ; Natarajan N; Shaw DWW; Apkon SD; Koo KSH; Shivaram GM; Monroe EJ
    Pediatr Radiol; 2018 Mar; 48(3):392-397. PubMed ID: 29130140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cone-beam computed tomography guided nusinersen administrations in adult spinal muscular atrophy patients with challenging access: a single- center experience.
    Salapura V; Snoj Z; Leonardis L; Koritnik B; Kostadinova V
    Radiol Oncol; 2022 Aug; 56(3):319-325. PubMed ID: 35962954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy.
    Stolte B; Totzeck A; Kizina K; Bolz S; Pietruck L; Mönninghoff C; Guberina N; Oldenburg D; Forsting M; Kleinschnitz C; Hagenacker T
    Ther Adv Neurol Disord; 2018; 11():1756286418803246. PubMed ID: 30305849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Experience with Nusinersen Application via an Intrathecal Port and Catheter System in Spinal Muscular Atrophy.
    Flotats-Bastardas M; Hahn A; Schwartz O; Linsler S; Meyer S; Kolodziej M; Koehler C
    Neuropediatrics; 2020 Dec; 51(6):401-406. PubMed ID: 33091940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections.
    Weaver JJ; Hallam DK; Chick JFB; Vaidya S; Shin DS; Natarajan N; Rad N; Reis J; Koo KSH; Shivaram GM; Thibodeau A; Apkon S; Monroe EJ
    J Neurointerv Surg; 2021 Jan; 13(1):75-78. PubMed ID: 32471828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrasound assisted lumbar intrathecal administration of nusinersen in adult patients with spinal muscular atrophy: A case series.
    Zanfini BA; Catarci S; Patanella AK; Pane M; Frassanito L; Filipponi E; Mercuri E; Sabatelli M; Draisci G
    Muscle Nerve; 2021 Nov; 64(5):594-599. PubMed ID: 34396547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transverse interlaminar ultrasound-guided C1-C2 puncture for the intrathecal administration of nusinersen in patients with spinal muscular atrophy.
    Yuan Q; Cui X; Zhang J; Dai Y; Feng F; Huang Y; Zhang S
    Muscle Nerve; 2024 Jul; ():. PubMed ID: 39049699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
    Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
    CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach.
    Bortolani S; Stura G; Ventilii G; Vercelli L; Rolle E; Ricci F; Bergui M; Mongini T
    Neuromuscul Disord; 2019 Oct; 29(10):742-746. PubMed ID: 31604650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity.
    Papaliagkas V; Foroglou N; Toulios P; Moschou M; Gavriilaki M; Notas K; Chatzikyriakou E; Zafeiridou G; Arnaoutoglou M; Kimiskidis VK
    Case Rep Neurol; 2021; 13(3):710-715. PubMed ID: 34950009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy.
    Cordts I; Lingor P; Friedrich B; Pernpeintner V; Zimmer C; Deschauer M; Maegerlein C
    Ther Adv Neurol Disord; 2020; 13():1756286419887616. PubMed ID: 32010224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
    Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
    Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.